These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38828669)

  • 21. Natural compounds as potential treatments of NF2-deficient schwannoma and meningioma: cucurbitacin D and goyazensolide.
    Spear SA; Burns SS; Oblinger JL; Ren Y; Pan L; Kinghorn AD; Welling DB; Chang LS
    Otol Neurotol; 2013 Oct; 34(8):1519-27. PubMed ID: 23928514
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regulation of mTOR complex 2 signaling in neurofibromatosis 2-deficient target cell types.
    James MF; Stivison E; Beauchamp R; Han S; Li H; Wallace MR; Gusella JF; Stemmer-Rachamimov AO; Ramesh V
    Mol Cancer Res; 2012 May; 10(5):649-59. PubMed ID: 22426462
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Spatially Resolved and Quantitative Analysis of the Immunological Landscape in Human Meningiomas.
    Yeung J; Yaghoobi V; Aung TN; Vesely MD; Zhang T; Gaule P; Gunel M; Rimm DL; Chen L
    J Neuropathol Exp Neurol; 2021 Jan; 80(2):150-159. PubMed ID: 33393633
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PD-1/PD-L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway.
    Zhao R; Song Y; Wang Y; Huang Y; Li Z; Cui Y; Yi M; Xia L; Zhuang W; Wu X; Zhou Y
    Cell Prolif; 2019 May; 52(3):e12571. PubMed ID: 30714229
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neurofibromatosis Type 2 (NF2) and the Implications for Vestibular Schwannoma and Meningioma Pathogenesis.
    Bachir S; Shah S; Shapiro S; Koehler A; Mahammedi A; Samy RN; Zuccarello M; Schorry E; Sengupta S
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33445724
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human Endogenous Retrovirus Type K Promotes Proliferation and Confers Sensitivity to Antiretroviral Drugs in Merlin-Negative Schwannoma and Meningioma.
    Maze EA; Agit B; Reeves S; Hilton DA; Parkinson DB; Laraba L; Ercolano E; Kurian KM; Hanemann CO; Belshaw RD; Ammoun S
    Cancer Res; 2022 Jan; 82(2):235-247. PubMed ID: 34853069
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activation of Yes-Associated Protein in Low-Grade Meningiomas Is Regulated by Merlin, Cell Density, and Extracellular Matrix Stiffness.
    Tanahashi K; Natsume A; Ohka F; Motomura K; Alim A; Tanaka I; Senga T; Harada I; Fukuyama R; Sumiyoshi N; Sekido Y; Wakabayashi T
    J Neuropathol Exp Neurol; 2015 Jul; 74(7):704-9. PubMed ID: 26049897
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK.
    Chang LS; Oblinger JL; Smith AE; Ferrer M; Angus SP; Hawley E; Petrilli AM; Beauchamp RL; Riecken LB; Erdin S; Poi M; Huang J; Bessler WK; Zhang X; Guha R; Thomas C; Burns SS; Gilbert TSK; Jiang L; Li X; Lu Q; Yuan J; He Y; Dixon SAH; Masters A; Jones DR; Yates CW; Haggarty SJ; La Rosa S; Welling DB; Stemmer-Rachamimov AO; Plotkin SR; Gusella JF; Guinney J; Morrison H; Ramesh V; Fernandez-Valle C; Johnson GL; Blakeley JO; Clapp DW;
    PLoS One; 2021; 16(7):e0252048. PubMed ID: 34264955
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histone deacetylase inhibitor AR-42 differentially affects cell-cycle transit in meningeal and meningioma cells, potently inhibiting NF2-deficient meningioma growth.
    Burns SS; Akhmametyeva EM; Oblinger JL; Bush ML; Huang J; Senner V; Chen CS; Jacob A; Welling DB; Chang LS
    Cancer Res; 2013 Jan; 73(2):792-803. PubMed ID: 23151902
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NF2 regulates IP3R-mediated Ca
    Lei Z; Niu J; Cai H; Kong Z; Ding X; Dong Y; Zhang D; Li X; Shao J; Lin A; Zhou R; Yang S; Yan Q
    FASEB J; 2024 Jul; 38(13):e23737. PubMed ID: 38953724
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Difference in the hypoxic immunosuppressive microenvironment of patients with neurofibromatosis type 2 schwannomas and sporadic schwannomas.
    Tamura R; Morimoto Y; Sato M; Kuranari Y; Oishi Y; Kosugi K; Yoshida K; Toda M
    J Neurooncol; 2020 Jan; 146(2):265-273. PubMed ID: 31897926
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The expression of the MSC-marker CD73 and of NF2/Merlin are correlated in meningiomas.
    Kirches E; Steffen T; Waldt N; Hebert E; Pachow D; Wilisch-Neumann A; Keilhoff G; Schneider T; Braunsdorf WEK; Warnke JP; Mawrin C
    J Neurooncol; 2018 Jun; 138(2):251-259. PubMed ID: 29468444
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 35. Efficient ADCC killing of meningioma by avelumab and a high-affinity natural killer cell line, haNK.
    Giles AJ; Hao S; Padget M; Song H; Zhang W; Lynes J; Sanchez V; Liu Y; Jung J; Cao X; Fujii R; Jensen R; Gillespie D; Schlom J; Gilbert MR; Nduom EK; Yang C; Lee JH; Soon-Shiong P; Hodge JW; Park DM
    JCI Insight; 2019 Oct; 4(20):. PubMed ID: 31536478
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP.
    Striedinger K; VandenBerg SR; Baia GS; McDermott MW; Gutmann DH; Lal A
    Neoplasia; 2008 Nov; 10(11):1204-12. PubMed ID: 18953429
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Programmed Cell Death-1: Programmed Cell Death-Ligand 1 Interaction Protects Human Cardiomyocytes Against T-Cell Mediated Inflammation and Apoptosis Response In Vitro.
    Tay WT; Fang YH; Beh ST; Liu YW; Hsu LW; Yen CJ; Liu PY
    Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32244307
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NF2 mutation status and tumor mutational burden correlate with immune cell infiltration in meningiomas.
    Rutland JW; Gill CM; Loewenstern J; Arib H; Pain M; Umphlett M; Kinoshita Y; McBride RB; Bederson J; Donovan M; Sebra R; Shrivastava RK; Fowkes M
    Cancer Immunol Immunother; 2021 Jan; 70(1):169-176. PubMed ID: 32661686
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular alterations in the neurofibromatosis type 2 gene and its protein rarely occurring in meningothelial meningiomas.
    Evans JJ; Jeun SS; Lee JH; Harwalkar JA; Shoshan Y; Cowell JK; Golubic M
    J Neurosurg; 2001 Jan; 94(1):111-7. PubMed ID: 11147878
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Merlin expression in secretory meningiomas: evidence of an NF2-independent pathogenesis? Immunohistochemical study.
    Buccoliero AM; Gheri CF; Castiglione F; Ammannati F; Gallina P; Taddei A; Garbini F; Rossi Degl'Innocenti D; Arganini L; Di Lorenzo N; Mennonna P; Taddei GL
    Appl Immunohistochem Mol Morphol; 2007 Sep; 15(3):353-7. PubMed ID: 17721284
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.